Showing 2644 results
- Media Release /Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients[1…
- Media Release /Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.…
- Key Release /In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio®* (teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary…
- Media Release /PARAGON-HF trial will provide Entresto® (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF)[1] New PROVE-HF and EVALUATE-HF studies will…
- Media Release /Sandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit Ruling prevents launch of important, affordable treatment option for US patients affected by chronic…
- Media Release /Basel, August 6, 2019 – Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma® (onasemnogene abeparvovec-xioi). First and…
- Media Release /Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many…
- Media Release /New European data from IMAS survey show that people living with axial spondyloarthritis (axSpA) suffer a delay in diagnosis of over 7 years, potentially leading to an increase in work-related…
- Media Release /Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg[1] Data at 2 years demonstrate over 50% of adults with…
- Media Release /First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide[1…
Pagination
- ‹ Previous page
- 1
- …
- 223
- 224
- 225
- 226
- 227
- 228
- 229
- …
- 265
- › Next page